9640 Medical Center Drive
Rockville, MD 20850

301.517.5556 Telephone
301.315.2438 Facsimile

Contacts: Douglas A. Doerfler
President & CEO
MaxCyte, Inc.
(301) 517-5556
dougd@maxcyte.com

Duncan Stewart, M.D.
Chief Scientific Officer
Northern Therapeutics, Inc.
(416) 864-5724
stewartd@smh.toronto.on.ca

FOR IMMEDIATE RELEASE

MAXCYTE AND NORTHERN THERAPEUTICS COLLABORATE TO DEVELOP PRODUCTS FOR PULMONARY DISEASES

Biotechs Combine Expertise to Develop Non-Viral Gene Therapies

Rockville, MD and Montreal, Canada – February 3, 2003 – MaxCyte, Inc. and Northern Therapeutics Inc. announced today a collaboration and license agreement to develop multiple non-viral gene-based products to treat pulmonary diseases utilizing MaxCyte's proprietary cell loading system. The agreement provides MaxCyte with up-front and milestone payments, research and development funding, and royalties for products developed from the collaboration. Financial terms of the agreement were not disclosed.

Northern Therapeutics has developed a novel cell-based gene therapy for pulmonary arterial hypertension and other chronic life-threatening pulmonary disorders. This technology provides a unique platform for the regeneration of damaged lung tissue and will be used to address severe pulmonary conditions for which there are currently no satisfactory treatment options. In this collaboration, MaxCyte and Northern Therapeutics will aim to develop gene-based therapeutics for specific indications that can be administered at a patient's bedside. The companies expect to file their first investigational new drug (IND) application with the U.S. Food and Drug Administration this year.

"We are pleased to collaborate with Northern Therapeutics in order to bring the company's impressive gene therapy technology to fruition," said Douglas Doerfler, president and CEO of MaxCyte. "MaxCyte is playing a key role in making non-viral gene therapy the preferred therapeutic option."

"This strategic partnership provides Northern Therapeutics with a non-viral gene delivery platform to realize the full potential of our gene discoveries," said Dr. Duncan Stewart, chief scientific officer of Northern Therapeutics. "It was important for us to partner with

a leader in non-viral gene delivery to advance our program to the clinic." Dr. Stewart, who also serves as chief of cardiology at St. Michael's Hospital and director and Dexter H.C. Man chair of cardiology at the University of Toronto, and has earned international recognition for his work in cardiopulmonary gene therapy, will direct the program.

About MaxCyte

MaxCyte, Inc., a clinical stage biotechnology company, is commercializing the most efficient and customizable cell loading technology available today. MaxCyte's pipeline includes one therapeutic in Phase I clinical trials and numerous late stage preclinical therapeutic candidates in oncology, cardiovascular and genetic diseases. MaxCyte is enabling and improving non-viral therapeutic gene transfer, identifying more targeted ways to deliver drugs, and accelerating the drug discovery process. Biopharmaceutical research and development applications include high throughput drug discovery, biopharmaceutical production and clinical monitoring. For more information, visit http://www.maxcyte.com.

About Northern Therapeutics

Northern Therapeutics' platform technology for autologous gene therapy serves as the focus of its business strategy to develop and commercialize treatments for pulmonary and cardiovascular diseases. Northern Therapeutics' largest shareholder is United Therapeutics Corporation (NASDAQ: UTHR) and Northern Therapeutics is the Canadian distributor for Remodulin®, HeartBar® and other United Therapeutics products.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated.

###